Naloxone Composition With Magnesium Chloride for Rapid Absorption

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing pharmaceutical compositions for treating opioid overdose suffer from a lag time in achieving therapeutic levels due to slow absorption, which can lead to inadequate treatment and potential morbidity or mortality.

Innovation Solution

A parenteral pharmaceutical composition comprising naloxone or a pharmaceutically acceptable salt thereof, combined with magnesium chloride as an absorption-enhancing adjuvant, to enhance systemic absorption and achieve rapid onset of action.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If intramuscular or subcutaneous injection of naloxone is used to treat opioid overdose, then the antidote can be administered effectively, but there is a lag time before therapeutic levels are achieved due to slow absorption

Engineering Contradiction:
Improveeffectiveness of antidote treatmentVSAvoidlag time to achieve therapeutic levels
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent changes the physical-chemical parameters of the naloxone formulation by incorporating magnesium chloride and adjusting pH to between 3.5 and 5.5, creating a microsphere formulation that enables rapid absorption while maintaining reliability of treatment

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses a composite material system consisting of naloxone combined with magnesium chloride in a microsphere formulation, where the composite structure provides both rapid absorption and sustained therapeutic effect, resolving the contradiction between speed and reliability

Inventive Principle:
Principle #40Composite materials

2Reliability

If conventional naloxone formulations are administered, then opioid overdose can be treated, but the onset of action is delayed which may result in inadequate treatment

Engineering Contradiction:
Improveadequacy of treatmentVSAvoidonset of action
Core Design Contradiction:
ReliabilityVSSpeed

Solution Approach 1:

The patent modifies key formulation parameters including pH (3.5-5.5), ionic strength, and composition by incorporating magnesium chloride to create a formulation that achieves rapid onset of action within minutes while ensuring adequate and reliable treatment of opioid overdose

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent introduces magnesium chloride as an intermediary substance that facilitates rapid absorption of naloxone, acting as a mediator between the administered antidote and the bloodstream to achieve both speed and reliability of treatment

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition provides a quicker onset of action and superior pharmacokinetics, with a time to maximum plasma concentration of naloxone in 12 minutes or less, significantly reducing the risk of morbidity and mortality from opioid overdoses.

Implementation Method 1

an adjuvant that promotes, augments, or quickens the systemic absorption rate of the naloxone post intramuscular or subcutaneous injection

Methodology Applied
Scientific EffectAbsorption enhancement: Absorption (physical)

Data Source

PatentEP4117629B1Compositions and medical use of naloxone
Publication Date: 2026.04.15 KNOA PHARMA LLC
  • EP4117629B1 patent drawingFigure 1

AI summary

Disclosed in certain embodiments is a formulation comprising a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof and an adjuvant that enhances the absorption of the naloxone into the systemic circulation of a subject. Also disclosed herein are a method of treatment and a kit that may be utilized in treatment.